N-Power Medicine, a company leading the reinvention of the clinical trial process, announced the acquisition of Syapse Holdings Inc. (“Syapse”), a pioneer in precision medicine solutions for community cancer centers. The integration of Syapse into N-Power Medicine incorporates Syapse’s extensive network of community-based health systems, with more than 1,000 oncologists, its data and technology stack, and its dedicated team.
N-Power partners with community oncologists through its proprietary real-time Kaleido Registry and AI-enabled point-of-care platform, complemented by virtual and on-site support, to optimize research and patient care workflows. This transaction will establish the largest community-based prospective clinical research network where every patient, through N-Power’s platform, will have research-ready data and documentation as part of their routine care. The expanded N-Power network will also help address critical gaps in patient access to clinical trials in the community setting, where more than 80% of U.S. cancer patients—particularly those from diverse and underrepresented populations—receive their care.
The transaction will enhance the company’s current offerings to its growing set of pharmaceutical customers, including Merck, which is engaged in a multi-trial collaboration with N-Power. N-Power can now provide significantly greater access to a more representative group of geographically diverse, U.S. community-based cancer patients for clinical trial enrollment. Greater network scale will also enable the rapid and rigorous generation of prospective external controls, allowing for smaller and faster clinical trials.
Also Read: CellFE and Syenex Partner to Enhance Cell Engineering
“The integration of Syapse into N-Power underscores our commitment to dramatically accelerating drug development and improving the probability of success by seamlessly integrating clinical research into every oncologist’s practice and every cancer patient’s care,” said Mark Lee, M.D., Ph.D, the Co-Founder and Chief Executive Officer of N-Power Medicine. “With this scale, N-Power accelerates the transformation of drug development that our pharma customers are asking for – enabling local access to clinical trials for more community oncologists and community cancer patients than ever before, and by creating a unique platform for generating prospective external controls, reducing the need for randomized trials.”
“Syapse joining N-Power represents a transformative step forward in our shared mission to revolutionize community-based patient care. By building upon Syapse’s existing offerings for its health system and pharma partners with N-Power’s AI-enabled ‘human-in-the-loop’ approach, we can significantly expand access to prospective clinical trials and life-saving innovations for patients in community settings,” said Michael Mentesana, the Chief Executive Officer of Syapse. “We are proud to join N-Power in building a future where community oncology serves as a powerful catalyst for research and improved patient outcomes.”
SOURCE: Businesswire